Biopharma Business Development & M&A: Solutions for Advancing Deals in Today's Economic Environment

3:00 PM - 4:00 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 206AB
While the biotech industry has seen record years of venture investment, crossover investments, and IPOs, we have recently seen a slowdown in these activities, and private companies are now seeking new avenues for raising capital within the challenging biotech financing environment. Now, more than ever, venture-backed biotechs are looking to Big Biopharma to step up BD partnerships (for non-dilutive capital) and M&A transactions (to exit). This panel will discuss the trickle-down effect of current macroeconomic drivers to capital markets as well as Big Pharma strategic plans and deal priorities/parameters to public/private biotech financing needs. By engaging executives who have engineered some of the biggest recent deals, we will evaluate a diversity of approaches and how this trickle-down effect is dictating changes in deal types, deal structures, and key terms.
Venture Partner
Playground Global
VP, Corporate Development
Biohaven Pharmaceuticals
Chief Business Development Officer
Good Therapeutics
Vice President
Johnson & Johnson Innovation
Executive Director